Does Fatty Liver Cause Constipation?

Fatty liver disease and constipation are two conditions that frequently occur together, leading many people to wonder whether one causes the other. Does fatty liver cause constipation? While there is no established direct causal link, the two share overlapping risk factors including a low-fibre diet, physical inactivity, and insulin resistance, and may be connected through the gut-liver axis. Understanding how fatty liver disease can influence digestion, what else might be contributing to constipation, and when to seek medical advice is essential for managing both conditions effectively.

Can fatty liver disease actually cause constipation?

Fatty liver disease does not directly cause constipation, but both conditions share risk factors such as low-fibre diet and inactivity, and may be indirectly linked through the gut-liver axis.

Fatty liver disease is not a direct, established cause of constipation, but the two conditions frequently occur together and share overlapping risk factors that can make bowel habits worse. Fatty liver disease, known medically as hepatic steatosis, occurs when excess fat accumulates in liver cells. In its more common form, metabolic dysfunction-associated steatotic liver disease (MASLD, previously called non-alcoholic fatty liver disease or NAFLD), it is closely linked to obesity, insulin resistance, and a diet high in processed foods and refined sugars.^[3][4]

Current evidence does not support a direct causal link between fatty liver disease and constipation. The association is largely observational, and the two conditions appear to share common risk factors rather than one causing the other. However, the gut and liver are connected through what researchers call the gut-liver axis, a two-way communication pathway involving the gut microbiome, bile acids, and the immune system. Disruption to this axis in people with fatty liver disease may indirectly influence bowel motility and stool consistency, though this remains an area of ongoing research rather than established fact.

It is also worth noting that bile acid diarrhoea is caused by excess bile acids reaching the colon (malabsorption), rather than by simple bile acid deficiency, so the relationship between bile acids and bowel habit is more complex than it might first appear.^[10][11]

Importantly, many of the lifestyle factors that contribute to fatty liver disease, including a low-fibre diet, physical inactivity, and excess body weight, are also well-recognised causes of constipation. This means that while fatty liver disease does not directly cause constipation, the two conditions often share the same root causes and can reinforce one another. Understanding this relationship is important for managing both effectively.

How does fatty liver disease affect your digestion and bowel habits?

Fatty liver disease can alter bile acid metabolism and gut microbiome composition, which may contribute to slower bowel transit and harder stools, though these are proposed associations rather than confirmed causal pathways.

In people with fatty liver disease or MASLD, digestive symptoms including constipation are commonly reported, though the mechanisms are not fully established. MASLD is not typically a cholestatic condition (one that impairs bile flow), so claims that it directly reduces bile production require careful qualification. That said, bile acid metabolism is altered in people with MASLD, and this may have downstream effects on fat digestion and bowel transit, though the evidence for this in early-stage disease is limited.

In people with more advanced liver disease, including those with significant fibrosis or cirrhosis, changes in gut motility are better documented. Research has shown that liver disease can alter the composition of the gut microbiome, reducing populations of beneficial bacteria and increasing harmful ones. This dysbiosis may impair the production of short-chain fatty acids, which are important for maintaining the health of the bowel lining and supporting regular bowel movements.^[13][14] These findings are more clearly established in advanced liver disease than in early MASLD.

Additionally, some people with fatty liver disease experience a degree of systemic inflammation, which may affect the enteric nervous system, the network of nerves that controls gut movement. Even in earlier stages, the combination of altered bile acid metabolism and gut microbiome changes may contribute to slower bowel transit and harder stools, though these are proposed associations rather than confirmed causal pathways. These mechanisms help explain why digestive symptoms, including constipation, are commonly reported by people living with fatty liver disease, even if the relationship is not straightforward.

Other common gut symptoms linked to fatty liver disease

People with MASLD may experience bloating, nausea, indigestion, alternating bowel habits, and upper right abdominal discomfort, though early-stage fatty liver disease is often entirely symptom-free.

Constipation is just one of several digestive symptoms that some people with fatty liver disease may experience, and it is worth being aware of the broader picture. It is important to note that fatty liver disease in its early stages is often entirely silent, with no symptoms at all. When symptoms do occur, they are frequently non-specific.

Symptoms that some people with MASLD report include:

• Bloating and abdominal discomfort, particularly after meals, which may relate to impaired fat digestion or gut microbiome changes

• Nausea, especially in the morning or after fatty meals

• Indigestion or acid reflux, which is more common in people with obesity, a key risk factor for fatty liver disease

• Alternating bowel habits, where constipation and looser stools occur in cycles, sometimes resembling irritable bowel syndrome (IBS)

• Abdominal fullness or a sensation of pressure in the upper right abdomen, where the liver sits

These symptoms can overlap with many other conditions, including IBS, gallbladder disease, and coeliac disease. This overlap can make diagnosis challenging and underlines the importance of proper clinical assessment rather than self-diagnosis. If you are experiencing persistent gut symptoms alongside known or suspected liver problems, speaking to your GP is the appropriate first step.

What else could be causing your constipation alongside fatty liver?

Type 2 diabetes, hypothyroidism, certain medications, low-fibre diet, physical inactivity, IBS, and psychological factors can all independently cause constipation alongside fatty liver disease.

Several other conditions and factors commonly occur alongside fatty liver disease and may independently contribute to constipation, making it important not to attribute all bowel symptoms to the liver alone. Identifying the correct underlying cause is essential for effective management.

Metabolic and hormonal factors are particularly relevant. Type 2 diabetes and insulin resistance, which are strongly associated with MASLD, can cause autonomic neuropathy that slows gut motility. Hypothyroidism, another condition linked to metabolic dysfunction, is a well-recognised cause of constipation and may coexist with fatty liver disease.^[18][19]

Medications are a frequently overlooked cause. Several drugs commonly prescribed to people with metabolic conditions can cause or worsen constipation, including:

• Calcium channel blockers (used for blood pressure)

• Iron supplements

• Certain antidepressants

• Opioid-based pain relief

If you suspect a medicine you have been prescribed is contributing to constipation, do not stop taking it without first speaking to your GP or pharmacist, who can advise on alternatives or management strategies. You can also report suspected side effects from any medicine via the MHRA Yellow Card Scheme at yellowcard.mhra.gov.uk.

Dietary habits play a major role. A diet low in fibre and fluid intake, which is common in people who consume high amounts of ultra-processed foods, contributes to both fatty liver disease and constipation simultaneously.

Physical inactivity reduces gut motility and is a shared risk factor for both conditions. Irritable bowel syndrome (IBS) can cause constipation-predominant symptoms independently of liver function, and some research suggests an association between IBS and metabolic liver disease, though the evidence base is still developing.

Finally, psychological factors such as anxiety and depression, which are more common in people living with chronic conditions including fatty liver disease, can affect gut motility through the gut-brain axis. A thorough assessment by a GP or gastroenterologist can help identify which of these factors is most relevant in any individual case.

When should you see a GP about constipation and liver problems?

See your GP if constipation persists beyond three weeks, or if you experience blood in stools, unexplained weight loss, jaundice, or abdominal swelling, as these may indicate a more serious underlying condition.

You should see your GP if constipation is persistent, significantly affecting your quality of life, or accompanied by symptoms that suggest a more serious underlying condition. Most episodes of constipation resolve with dietary and lifestyle changes, but certain warning signs warrant prompt medical attention.

Contact your GP if you experience:

• Constipation lasting more than three weeks that does not improve with dietary changes

• Unexplained weight loss alongside changes in bowel habits

• Blood in your stools or on the toilet paper

• A noticeable change in the shape or consistency of your stools over several weeks

• Abdominal pain that is severe or worsening

• Yellowing of the skin or whites of the eyes (jaundice), which may indicate worsening liver function

• Significant swelling of the abdomen, which in the context of liver disease may suggest fluid accumulation (ascites)

Your GP may arrange blood tests to assess liver function, thyroid function, and blood glucose, as well as a review of any current medications. In line with NICE guidance on suspected cancer (NG12), your GP may also arrange a faecal immunochemical test (FIT) if you have a persistent change in bowel habit, particularly if you are aged 40 or over or have other relevant symptoms. This is a routine investigation and does not necessarily indicate a serious diagnosis, but it is an important step in ruling out other causes.

If you have a known diagnosis of fatty liver disease and develop new or worsening digestive symptoms, it is sensible to discuss these with your GP rather than assuming they are unrelated.

Call NHS 111 if you are unsure whether your symptoms need urgent attention. Call 999 or go to your nearest A&E only if you develop sudden, severe abdominal pain, collapse, or signs of significant bleeding. Routine concerns about constipation and liver health are best managed through your GP surgery, where a full clinical picture can be taken into account.

Diet and lifestyle changes that support both liver health and digestion

Increasing dietary fibre to 30g per day, following a Mediterranean-style diet, staying well hydrated, and taking regular physical activity are evidence-based strategies that benefit both liver health and bowel regularity.

Adopting a diet and lifestyle that supports liver health will, in most cases, also improve bowel regularity, since the two conditions share many of the same modifiable risk factors. NICE guideline NG49 on NAFLD (the previous term for MASLD) emphasises sustained lifestyle modification as the cornerstone of management.^[21][22]

Dietary changes to consider:

• Increase dietary fibre by eating more vegetables, legumes, wholegrains, and fruit. Fibre feeds beneficial gut bacteria, softens stools, and supports bile acid metabolism. Adults in the UK are advised to aim for 30 grams of fibre per day, according to NHS guidance.^[23][24]

• Stay well hydrated, aiming for around six to eight glasses of fluid per day, as adequate fluid intake is essential for fibre to work effectively in the bowel.

• Reduce ultra-processed foods, refined sugars, and saturated fats, which contribute to hepatic fat accumulation and may worsen gut dysbiosis.

• Consider a Mediterranean-style diet, which has a strong evidence base for reducing liver fat and improving metabolic health, and is naturally high in fibre and healthy fats. This is supported by EASL clinical practice guidelines on MASLD.

• Limit or avoid alcohol, in line with NHS alcohol guidelines, as alcohol can worsen liver inflammation and impair gut motility.

Lifestyle habits that help both conditions:

• Regular physical activity, such as 150 minutes of moderate-intensity exercise per week as recommended by NHS physical activity guidelines for adults, improves insulin sensitivity, reduces liver fat, and stimulates bowel motility.^[29]

• Gradual, sustained weight loss of 7 to 10 per cent of body weight has been shown in clinical studies to significantly reduce liver fat in people with MASLD, and is supported by EASL guidance.

• Managing stress through techniques such as mindfulness or cognitive behavioural therapy may also benefit gut function through the gut-brain axis.

For people exploring structured weight management support, Bolt Pharmacy is a GPhC-registered online pharmacy in Great Britain offering online weight-management consultations, with prescriber review and pharmacist support, alongside dietary and lifestyle options. Making consistent, evidence-based changes to diet and activity remains the most effective long-term strategy for both liver health and digestive wellbeing.

Scientific References

1. A multisociety Delphi consensus statement on new fatty liver disease nomenclature.
2. Understanding the evolving nomenclature of steatotic liver disease.
3. Exploring the Impact of Polychlorinated Biphenyls (PCBs) on the Development of MASLD: A Comprehensive Review.
4. MASH in Type 2 Diabetes: Pathophysiology, Diagnosis, and Therapeutic Management — A Narrative Review.
5. Metabolic Liver Disease Beyond the Liver: Association of MASLD with Cardiovascular and Renal Diseases.
6. Gut-Liver Axis, Microbiota, Bile Acids, and Immune System.
7. Gut microbiota modulates nonalcoholic fatty liver disease (NAFLD) progression via regulation of gluconeogenesis: mechanisms and translational research.
8. The liver-gut-brain axis in metabolic dysfunction-associated steatotic liver disease: bidirectional communication, clinical implications, and future perspectives.
9. The gut microbiota-bile acid-FXR axis in NAFLD: from progression to therapeutic applications.
10. Bile acid malabsorption: colesevelam — what is bile acid malabsorption.
11. Bile acid malabsorption: colesevelam — relevance to NICE guidance programmes.
12. Obeticholic acid for severe bile acid diarrhea with intestinal failure: A case report and review of the literature.
13. Comprehensive Overview of Gut Microbiota Alterations in Obesity and Related Chronic Diseases: A Narrative Review.
14. Gut microbiome and metabolic dysfunction-associated steatotic liver disease: Pathogenic role and potential for therapeutics.
15. Diabetic gastroenteropathy: Associations between gastrointestinal symptoms, motility, and extraintestinal autonomic measures.
16. Molecular mechanisms of enteric neuropathies in high-fat diet feeding and diabetes.
17. Diabetic gastroenteropathy: modern methods of diagnosis and treatment.
18. Underactive thyroid (hypothyroidism).
19. Thyroid disorders and gastrointestinal dysmotility: an old association.
20. Suspected cancer: recognition and referral (NG12).
21. Non-alcoholic fatty liver disease (NAFLD) — guideline NG49.
22. Non-alcoholic fatty liver disease (NAFLD).
23. How to get more fibre into your diet.
24. Fibre — British Dietetic Association.
25. EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease.
26. Impact of weight loss and reduction of ultra-processed foods on liver fat content in MASLD: A randomized controlled trial.
27. Very low energy ketogenic diet vs. Mediterranean diet for MASLD: Superior steatosis reduction in a randomised pilot study.
28. Mediterranean and low-fat diets are equally effective in MASLD resolution at 12 weeks regardless of PNPLA3 genotype: A randomized controlled trial.
29. Physical activity guidelines for adults aged 19 to 64.

Frequently Asked Questions